ALKS Alkermes plc
Price (delayed)
$33.285
Market cap
$5.41B
P/E Ratio
14.99
Dividend/share
N/A
EPS
$2.22
Enterprise value
$5.2B
Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by
Highlights
The debt has plunged by 80% YoY and by 79% from the previous quarter
The company's equity rose by 22% YoY and by 13% QoQ
ALKS's quick ratio is up by 15% year-on-year but it is down by 13% since the previous quarter
Alkermes's gross profit has decreased by 7% YoY but it has increased by 4.8% from the previous quarter
ALKS's P/E is 18% above its last 4 quarters average of 12.8
Key stats
What are the main financial stats of ALKS
Market
Valuations
Earnings
Shares outstanding
162.61M
Market cap
$5.41B
Enterprise value
$5.2B
Price to earnings (P/E)
14.99
Price to book (P/B)
3.68
Price to sales (P/S)
3.53
EV/EBIT
11.27
EV/EBITDA
10.61
EV/Sales
3.34
Revenue
$1.56B
Gross profit
$1.31B
Operating income
$420.64M
Net income
$367.07M
EBIT
$461.26M
EBITDA
$489.79M
Free cash flow
$504.03M
Per share
Balance sheet
Liquidity
EPS
$2.22
EPS diluted
$2.17
Free cash flow per share
$3.05
Book value per share
$9.05
Revenue per share
$9.42
TBVPS
$11.92
Total assets
$2.06B
Total liabilities
$590.59M
Debt
$75.54M
Equity
$1.46B
Working capital
$950.16M
Debt to equity
0.05
Current ratio
3.04
Quick ratio
2.44
Net debt/EBITDA
-0.44
Margins
Efficiency
Dividend
EBITDA margin
31.4%
Gross margin
84.2%
Net margin
23.6%
Operating margin
27%
Return on assets
17.2%
Return on equity
27.7%
Return on invested capital
31.5%
Return on capital employed
29%
Return on sales
29.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALKS stock price
How has the Alkermes stock price performed over time
Intraday
-0.37%
1 week
-3.94%
1 month
-7.54%
1 year
15.61%
YTD
15.73%
QTD
15.73%
Financial performance
How have Alkermes's revenue and profit performed over time
Revenue
$1.56B
Gross profit
$1.31B
Operating income
$420.64M
Net income
$367.07M
Gross margin
84.2%
Net margin
23.6%
Alkermes's operating income has increased by 35% from the previous quarter
The company's operating margin rose by 30% QoQ and by 8% YoY
Alkermes's net income has increased by 10% from the previous quarter and by 3.2% YoY
The net margin has grown by 10% YoY and by 7% from the previous quarter
Growth
What is Alkermes's growth rate over time
Valuation
What is Alkermes stock price valuation
P/E
14.99
P/B
3.68
P/S
3.53
EV/EBIT
11.27
EV/EBITDA
10.61
EV/Sales
3.34
ALKS's P/E is 18% above its last 4 quarters average of 12.8
The EPS is up by 10% since the previous quarter and by 3.7% year-on-year
The company's equity rose by 22% YoY and by 13% QoQ
The P/B is 9% higher than the last 4 quarters average of 3.4 and 5% higher than the 5-year quarterly average of 3.5
ALKS's P/S is 22% above its last 4 quarters average of 2.9 and 11% above its 5-year quarterly average of 3.2
The revenue has contracted by 6% YoY but it has grown by 3.5% from the previous quarter
Efficiency
How efficient is Alkermes business performance
The ROS has soared by 75% year-on-year and by 47% since the previous quarter
The ROIC has soared by 56% from the previous quarter and by 55% YoY
The ROA rose by 11% QoQ and by 3% YoY
The return on equity has declined by 6% year-on-year but it has increased by 4.5% since the previous quarter
Dividends
What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALKS.
Financial health
How did Alkermes financials performed over time
The company's total liabilities fell by 37% YoY and by 32% QoQ
ALKS's quick ratio is up by 15% year-on-year but it is down by 13% since the previous quarter
The debt is 95% less than the equity
The debt to equity has plunged by 84% YoY and by 82% from the previous quarter
The debt has plunged by 80% YoY and by 79% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.